论文部分内容阅读
包虫病(棘球蚴病),其治疗方法至今仍以外科手术为主,但对某些复杂的多发性、多脏器或多次手术后复发的病例,以及泡球蚴患者,手术治疗往往不够满意,只能作姑媳性手术,甚且不能手术。1974年 Heath 等人首先报道了甲苯咪唑(Mebendazole 简称 MBz),治疗鼠泡(棘)球蚴病有高效,随后为许多学者所证实。1977年开始应用于包虫病人的临床试验性治疗,到1979年国外已报道了250余例包虫病患者接受 MB2治疗,近期效果比较满意。我所在建成多种包虫病动物模型并观察了小白鼠包虫病的某些发育规律性基础上,开始了在体外及体内筛选抗棘球蚴病药物的研究。基于国产甲苯咪唑治
Echinococcosis (hydatid disease), the treatment is still the main surgical, but for some complicated multiple, multiple or multiple recurrence cases, as well as patients with cysticercosis, surgical treatment Often unsatisfied, only for auntie sex surgery, and can not surgery. In 1974, Heath et al. First reported that mebendazole (MBz) was effective in the treatment of murine (spine) echinococcosis and subsequently confirmed by many scholars. Since 1977, it has been applied to clinical trial of hydatid disease in patients. By 1979, more than 250 cases of hydatid disease were reported to have received MB2 treatment abroad, and the recent results were satisfactory. Based on the establishment of various animal models of hydatid disease and the observation of certain developmental regularities of mouse echinococcosis, we started to screen anti-hydatid disease drugs in vitro and in vivo. Based on domestic mebendazole treatment